Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)

Withdrawn before enrolling · Phase 2

Conditions studied: Venous Thromboembolism

In brief

This study was designed to assess the safety and efficacy of GW813893 in the prophylaxis of VTE following TKR and to provide evidence to enable the selection of the appropriate dose(s) and dose regimen of GW813893 for future investigation.

Key facts

Study ID

NCT00541320

Run by

GlaxoSmithKline

People needed

0

Starts

2007-02-01

Last updated by the study team

2013-04-04

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are scheduled for primary elective unilateral total knee arthroplasty.

You may not qualify if…

• Women who are not surgically sterile or post-menopausal
• Have a contra-indication to contract venography
• Have a known disorder associated with increased risk of bleeding or have been immobile up to 12 weeks before surgery.

Where it is running

• GSK Clinical Trials Call Center — Birmingham, Alabama, United States
• GSK Clinical Trials Call Center' — Phoenix, Arizona, United States
• GSK Clinical Trials Call Center — Phoenix, Arizona, United States
• GSK Clinical Trials Call Center — Yuba City, California, United States
• GSK Clinical Trials Call Center — St. Petersburg, Florida, United States
• GSK Clinical Trials Call Center — Decatur, Georgia, United States
• GSK Clinical Trials Call Center — Charleston, South Carolina, United States
• GSK Clinical Trials Call Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.